DADr. Agarwals Health Care544350Scheme implementation

Scheme of Amalgamation effective November 01, 2026; record date November 18, 2026 for consideration shares

Dr. Agarwal's Health Care Ltd has fixed Wednesday, November 18, 2026 as the record date for allotting consideration shares to eligible shareholders of Dr. Agarwal's Eye Hospital Ltd under their Scheme of Amalgamation.

By ScoutQuest · Tue 20 Oct 2026, 7:12 PM IST · 2 min read

Record Date

Wednesday, November 18, 2026

Share Exchange Ratio

23 equity shares of ₹1 each for every 2 equity shares of ₹10 each held

Authorised Share Capital After Merger

₹110,00,00,000

Scheme effective from November 01, 2026

The Board of Dr. Agarwal's Health Care Ltd met on October 20, 2026 and took on record the certified copy of the order dated September 30, 2026 passed by the National Company Law Tribunal, Chennai Bench, sanctioning the Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Ltd (Transferor Company) and Dr. Agarwal's Health Care Ltd (Transferee Company). With the certified copy shared in Form INC-28 with the Registrar of Companies, Chennai, on October 15, 2026, the conditions specified under Clause 24 of the Scheme stand satisfied.

Accordingly, the Scheme becomes effective and operative from November 01, 2026, with the Appointed Date being April 01, 2026.

Record date and share exchange ratio

• The record date to determine eligible equity shareholders of Dr. Agarwal's Eye Hospital Ltd entitled to receive consideration shares is Wednesday, November 18, 2026.
• The approved ratio is 23 fully paid-up equity shares of face value ₹1 each of Dr. Agarwal's Health Care Ltd for every 2 fully paid-up equity shares of face value ₹10 each held in Dr. Agarwal's Eye Hospital Ltd.

Changes to authorised share capital

• The Transferor Company's existing authorised capital of 2 crore equity shares of face value ₹10 each stands reclassified into 20 crore equity shares of face value ₹1 each.
• On the Scheme becoming effective, that entire reclassified authorised capital of ₹20 crore stands combined and merged with the authorised share capital of the Transferee Company.
• Before effectiveness, the Transferee Company's authorised capital was ₹90,00,00,000, made up of 54.2 crore equity shares of INR 1 each and 35,80,000 fully and compulsorily convertible non-cumulative participating preference shares of INR 100 each.
• After effectiveness, the authorised capital becomes ₹110,00,00,000, made up of 74.2 crore equity shares of INR 1 each and the same 35,80,000 preference shares of INR 100 each.

What this means for a retail holder

• If you hold shares of Dr. Agarwal's Eye Hospital Ltd, your name must appear in the register on the record date of November 18, 2026 to receive the consideration shares of Dr. Agarwal's Health Care Ltd in the 23-for-2 ratio.
• These are authorised capital figures, which set the ceiling up to which shares can be issued; the increase to ₹110,00,00,000 happens because the Transferor Company's reclassified authorised capital is merged into the Transferee Company.
• The Scheme's commercial terms, including the exchange ratio, were fixed earlier; this intimation covers the effective date, the record date and the consequential authorised capital change.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev